Susquehanna International Group’s Beam Therapeutics BEAM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$4.78M Buy
200,400
+76,900
+62% +$2.13M ﹤0.01% 4317
2025
Q4
$3.42M Buy
123,500
+24,500
+25% +$625K ﹤0.01% 4645
2025
Q3
$2.4M Sell
99,000
-557,600
-85% -$11.1M ﹤0.01% 5402
2025
Q2
$11.2M Buy
656,600
+532,200
+428% +$9.27M ﹤0.01% 2685
2025
Q1
$2.43M Buy
124,400
+60,400
+94% +$1.58M ﹤0.01% 5106
2024
Q4
$1.59M Sell
64,000
-48,700
-43% -$1.24M ﹤0.01% 5819
2024
Q3
$2.76M Buy
112,700
+1,600
+1% +$41.3K ﹤0.01% 4704
2024
Q2
$2.6M Sell
111,100
-102,400
-48% -$2.52M ﹤0.01% 4577
2024
Q1
$7.05M Buy
213,500
+164,600
+337% +$5.13M ﹤0.01% 3114
2023
Q4
$1.33M Sell
48,900
-183,100
-79% -$4.55M ﹤0.01% 6282
2023
Q3
$5.58M Buy
232,000
+180,400
+350% +$4.84M ﹤0.01% 3338
2023
Q2
$1.65M Sell
51,600
-190,700
-79% -$6.19M ﹤0.01% 5556
2023
Q1
$7.42M Buy
242,300
+126,300
+109% +$4.98M ﹤0.01% 2886
2022
Q4
$4.54M Buy
116,000
+59,600
+106% +$2.67M ﹤0.01% 3394
2022
Q3
$2.69M Sell
56,400
-80,400
-59% -$4.59M ﹤0.01% 4304
2022
Q2
$5.3M Sell
136,800
-13,800
-9% -$549K ﹤0.01% 3093
2022
Q1
$8.63M Buy
150,600
+18,500
+14% +$1.21M ﹤0.01% 2750
2021
Q4
$10.5M Sell
132,100
-19,900
-13% -$1.7M ﹤0.01% 2640
2021
Q3
$13.2M Sell
152,000
-11,200
-7% -$1.13M ﹤0.01% 2490
2021
Q2
$21M Buy
163,200
+43,100
+36% +$3.43M ﹤0.01% 1962
2021
Q1
$9.61M Buy
120,100
+53,100
+79% +$5.05M ﹤0.01% 2827
2020
Q4
$5.47M Buy
+67,000
New +$3.29M ﹤0.01% 3284

Other funds holding BEAM

Susquehanna International Group's BEAM Position: Q1 2026 in Review

Susquehanna International Group increased its Beam Therapeutics (BEAM) stake by 81% in Q1 2026, buying an estimated $2.22M and bringing the position to 178,391 shares worth $4.25M. The position accounts for ﹤0.01% of the portfolio, ranked #4544.

Susquehanna International Group first reported a position in BEAM in Q4 2020 and has held it in 22 quarters since. The position peaked at $10M in Q2 2025. 251 funds tracked by Wall St. Rank hold BEAM as of Q1 2026.

  • Susquehanna International Group held 178,391 shares of Beam Therapeutics worth $4.25M as of Q1 2026.
  • Susquehanna International Group bought 79,880 Beam Therapeutics shares in Q1 2026, an estimated $2.22M.
  • Beam Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #4544 holding.
  • Susquehanna International Group first reported a position in Beam Therapeutics in Q4 2020 and has held it in 22 quarters since.
  • Susquehanna International Group's Beam Therapeutics position peaked at $10M in Q2 2025.
  • 251 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.